These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

41 related items for PubMed ID: 18687501

  • 1. Glycaemic control and hypoglycaemia in the PRESENT study.
    Almustafa M, Yeo JP, Khutsoane D.
    Diabetes Res Clin Pract; 2008 Sep; 81 Suppl 1():S10-5. PubMed ID: 18687501
    [Abstract] [Full Text] [Related]

  • 2. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 3. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y, IMPROVE Study Group Expert Panel.
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [Abstract] [Full Text] [Related]

  • 4. Study design and baseline characteristics of patients in the PRESENT study.
    Shestakova M, Bech OM, Momani MS.
    Diabetes Res Clin Pract; 2008 Sep; 81 Suppl 1():S3-9. PubMed ID: 18672309
    [Abstract] [Full Text] [Related]

  • 5. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D, Sharma SK, Almustafa M, Jang HC, Azar ST, Danciulescu R, Shestakova M, Ayad NM, Guler S, Bech OM, PRESENT Study Group.
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [Abstract] [Full Text] [Related]

  • 6. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 7. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 8. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI, Lindström T, Eson Jennersjö P, Paulsson JF, Westermark GT, Olsson AG, Arnqvist HJ.
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [Abstract] [Full Text] [Related]

  • 9. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K, Dornhorst A, Sreenan S.
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V.
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [Abstract] [Full Text] [Related]

  • 11. Preoperative hypoglycemia in a patient receiving insulin detemir.
    Olson RP, Bethel MA, Lien L.
    Anesth Analg; 2009 Jun; 108(6):1836-8. PubMed ID: 19448209
    [Abstract] [Full Text] [Related]

  • 12. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Jun; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 13. Type 2 diabetes in primary care in belgium: need for structured shared care.
    Goderis G, Borgermans L, Heyrman J, Broeke CV, Grol R, Boland B, Mathieu C.
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):367-72. PubMed ID: 19358093
    [Abstract] [Full Text] [Related]

  • 14. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

  • 15. [Evaluating the feature of hypoglycemia detected by continuous glucose monitoring system during temporary continuous subcutaneous insulin infusion in type 2 diabetes patients].
    Li M, Zhou J, Bo YQ, Lu W, Jia WP, Xiang KS.
    Zhonghua Yi Xue Za Zhi; 2008 Jun 24; 88(24):1679-82. PubMed ID: 19024537
    [Abstract] [Full Text] [Related]

  • 16. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
    Yenigun M, Honka M.
    Int J Clin Pract; 2009 Mar 24; 63(3):425-32. PubMed ID: 19222627
    [Abstract] [Full Text] [Related]

  • 17. Hypoglycaemia and predisposing factors among clinical subgroups treated with intensive insulin therapy.
    Waeschle RM, Bräuer A, Hilgers R, Herrmann P, Neumann P, Quintel M, Moerer O.
    Acta Anaesthesiol Scand; 2014 Feb 24; 58(2):223-34. PubMed ID: 24372028
    [Abstract] [Full Text] [Related]

  • 18. Effect of obesity on incidence of type 2 diabetes declines with age among Japanese women.
    Fujita M, Ueno K, Hata A.
    Exp Biol Med (Maywood); 2009 Jul 24; 234(7):750-7. PubMed ID: 19429850
    [Abstract] [Full Text] [Related]

  • 19. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG.
    Acta Diabetol; 2009 Mar 24; 46(1):63-5. PubMed ID: 18825302
    [Abstract] [Full Text] [Related]

  • 20. A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS.
    Simon B, Treat V, Marco C, Rosenberg D, Joseph J, Hipszer B, Li Y, Chervoneva I, Padron-Massara L, Jabbour S.
    Int J Clin Pract; 2008 Dec 24; 62(12):1858-63. PubMed ID: 19166434
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.